AnaptysBio, Inc.
AnaptysBio, Inc. (Nasdaq: ANAB) is a clinical-stage biotechnology company developing antibody therapeutics for autoimmune and inflammatory diseases. Its wholly owned pipeline includes rosnilimab, which completed a Phase 2b trial for rheumatoid arthritis; ANB033, in Phase 1b trials for celiac disease and eosinophilic… From the company’s description.
Over the twelve months to Mar 31, 2026, AnaptysBio, Inc. reported revenue of $232.39M, up 107.7% from a year earlier, and a net loss of $26.79M. Its operating margin was 17.6%, and operations generated $4.48M in cash. In fiscal 2025, it reported revenue of $234.60M, up 157.0% from fiscal 2024, and a net loss of $13.23M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AnaptysBio, Inc. does
In the company’s own words
AnaptysBio, Inc. (Nasdaq: ANAB) is a clinical-stage biotechnology company developing antibody therapeutics for autoimmune and inflammatory diseases. Its wholly owned pipeline includes rosnilimab, which completed a Phase 2b trial for rheumatoid arthritis; ANB033, in Phase 1b trials for celiac disease and eosinophilic esophagitis; and ANB101, in a Phase 1a trial. The company also licenses antibody programs to collaborators: GSK develops Jemperli (dostarlimab), a PD-1 antagonist approved for several endometrial cancer indications, and Vanda holds global development and commercialization rights to imsidolimab, an IL-36R antagonist for generalized pustular psoriasis. AnaptysBio earns royalties and milestones from its GSK collaboration and license and transition-services revenue from Vanda. In September 2025, it announced plans to separate its royalty collaborations from its clinical-stage immunology business into two publicly traded companies. For 2025, GSK reported $1.1 billion in Jemperli sales. Its website is www.anaptysbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- June
- CIK
- 1370053
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AnaptysBio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · AnaptysBio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AnaptysBio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AnaptysBio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AnaptysBio, Inc.'s last four quarterly filings that the numbers alone won't show?”